

Erratum to: Dinutuximab: First Global Approval

Sohita Dhillon¹

Published online: 13 October 2015
© Springer International Publishing Switzerland 2015

Erratum to: *Drugs* (2015) 75:923–927 DOI 10.1007/s40265-015-0399-5

The author has alerted us to the following error:

Page 925, column 1, section 2.3.1.1, lines 6–12.

The sentence that previously read:

‘At a median follow-up of 2.1 months, dinutuximab recipients ($n = 113$ intent to treat) had significantly higher EFS rates (66 vs. 46 %; $p = 0.01$) and overall survival (OS) rates (86 vs. 75 %; $p = 0.02$) compared with standard therapy recipients ($n = 113$ intent to treat) in a randomized, open-label, phase III study (NCT00026312; ANBL0032).’

should read:

‘At a median follow-up of 2.1 years, dinutuximab recipients ($n = 113$ intent to treat) had significantly higher EFS rates (66 vs. 46 %; $p = 0.01$) and overall survival (OS) rates (86 vs. 75 %; $p = 0.02$) compared with standard therapy recipients ($n = 113$ intent to treat) in a randomized, open-label, phase III study (NCT00026312; ANBL0032).’

The online version of the original article can be found under
doi:[10.1007/s40265-015-0399-5](https://doi.org/10.1007/s40265-015-0399-5).

✉ Sohita Dhillon
dru@adis.com

¹ Springer, Private Bag 65901, Mairangi Bay, 0754 Auckland,
New Zealand